Reasons to Seek a Second Opinion When to Seek a Second Opinion How to Find a Doctor Questions to Ask What Happens Next? Many people with cancer can benefit from a second medical opinion. Those with ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...

The FDA has approved belzutifan (WELIREG, Merck) in combination with lenvatinib (Lenvima, Eisai) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) who have received a ...

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice. Brian I. Rini, MD, FASCO: So, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Genitourinary oncologists discuss the safety and efficacy of IO/TKI and IO/IO combination therapies in advanced renal cell carcinoma. Tian Zhang, M.D., M.H.S.: In terms of front-line therapies, as we ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary Cancers Symposium later this week in San Francisco, California. The new ...

The addition of SBRT to an immunotherapy doublet did not significantly affect safety outcomes among patients with de novo metastatic RCC. The trial’s rationale was rooted in the hypothesis that ...

Promoting to the front line two drugs normally used in rearguard action to treat advanced renal cell carcinoma (RCC) ― nivolumab (Opdivo) and cabozantinib (Cabometyx) ― doubled overall response rates ...

Please provide your email address to receive an email when new articles are posted on . MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal ...

Expert perspectives on the decision-making process for selecting frontline systemic therapy for patients with advanced renal cell carcinoma. Chandler H. Park, M.D.: One of the toughest parts of being ...

Treatment with toripalimab and axitinib can improve progression-free survival (PFS), when compared to sunitinib monotherapy, in patients with treatment-naïve, advanced renal cell carcinoma (RCC), a ...